CTOs on the Move


 
Color`s mission is to help people lead the healthiest lives that science and medicine can offer. We launched in April 2015 with a simple, affordable genetic test to help people understand their risk for hereditary cancer. In 2017, we added coverage for hereditary heart conditions.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.color.com
  • 831 Mitten Rd
    Burlingame, CA USA 94010
  • Phone: N/A

Executives

Name Title Contact Details
Coe Salzgeber
Senior Director, Data & Infrastructure Profile
Lisa Hall
Chief Information Security Officer Profile

Funding

Color raised $75M on 01/14/2020
Color raised $167M on 01/04/2021
Color raised $100M on 11/09/2021

Similar Companies

Tekmira Pharmaceuticals Corporation

Tekmira Pharmaceuticals Corporation is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Infinity BiologiX

RUCDR Infinite Biologics Becomes Infinity BiologiX IBX will continue to advance RUCDR`s founding mission to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. IBX will continue to collaborate with – and provide services to – researchers in both the public and private sectors globally, including innovative and market-disrupting sample collection and processing, storage and analytical services, and scientific and technical support in both the research and clinical arenas.

Copan Diagnostics

Copan Diagnostics is a Murrieta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EpicentRx Inc

EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment.

Pionyr Immunotherapeutics

Pionyr Immunotherapeutics discovers and develops first-in-class biologic drugs that fine-tune natural immune responses to increase immune defenses for diseases such as cancer, or to dampen immune responses in autoimmune diseases.